What to know about using non-insulin agents in type 1 diabetes

Susan Weiner, MS, RDN, CDCES, FADCES, talks with Joshua J. Neumiller, PharmD, CDCES, FADCES, FASCP, about nuances of using SGLT2 inhibitors and GLP-1 receptor agonists in type 1 diabetes, and a therapy for delaying type 1 diabetes onset.
Neumiller: Both SGLT2 inhibitors and GLP-1 receptor agonists have been studied in people with type 1 diabetes as add-on to background insulin therapy to improve glycemia, provide insulin-sparing effects, and aid with weight loss.
Studies with SGLT2 inhibitors in people with type 1 diabetes have reported modest reductions in HbA1c (0.2% to 0.4%), modest weight

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart